MedWatch

Bank bemused by Ambu downgrade

According to Handelsbanken, investor confidence in Ambu's credibility has suffered a blow after the company downgraded its guidance.

Photo: Ambu / PR

Analysts at the financial institution Handelsbanken are bemused that Ambu downgraded its guidance last year, since this move contrasts with announcements made by other contractors in the hospital sector, according to a stock exchange announcement from Handelsbanken on Monday.

On Thursday last week, Ambu downgraded its predicted guidance for the firm's organic growth and margin for earnings before interest and taxation for the staggered fiscal year 2020/2021 referring to the fact that the covid-19 pandemic is still affecting the number of operations being performed. This challenges the supply chain and causes delays.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs